Allscripts' Veradigm Business Line Unveils New Solution
Zacks Investment Research | Mar 08, 2020 09:20PM ET
Allscripts Healthcare Solutions, Inc.’s (NASDAQ:MDRX) Veradigm business line has recently introduced an exclusive new software solution for specialty medication management. The new solution — AccelRx — has been created to simplify specialty medication fulfillment and lower patient waiting times.
Notably, the new solution is likely to boost Allscript’s Veradigm business segment, which is committed toward streamlining the complex healthcare system with next-generation healthcare solutions. These solutions, as a result, improve quality, efficacy and value of healthcare.
Few Words About AccelRx
The new solution has been created to streamline the requirements necessary to distribute the growing number of specialty medications that are being prescribed. The solution leverages broad industry partnerships that have been built over decades of e-prescribing and previous authorization leadership that helps providers to cut down time on phone calls and faxes. This, in turn, will drive increasing medication adherence and improve patient care.
Benefits of the Solution
Healthcare providers are likely to benefit from this solution as it will help them in the reduction of time that takes to deliver the medications to patients.
With the growing importance of specialty medications and the impact that they have on healthcare in the United States, the number of patients and providers gaining from the value of AccelRx continues to grow as well. Thus, Allscript’s Veradigm business unit is focused in the development of ongoing partnerships with key industry stakeholders that will enable the expansion of the scope of enhancement of the AccelRx solution throughout 2020 and further.
Specialty medications represents 3% of all prescriptions written in the United States, in spite of that these medications are estimated to account for up to 50% of the total sped on prescription medications in 2020.
Market Prospects
Per a report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.